$220MSeries D, 6 May 2026
Proceeds fund the registration-enabling DOMMINO-1 and DOMMINO-2 trials of inobrodib in multiple myeloma.
- Amount
- $220M
- Stage
- Series D
- Announced
- 6 May 2026
- Lead
- Venrock Healthcare Capital Partners
- Other investors
- Fidelity, Pfizer, Forbion, RA Capital Management, Sofinnova Partners
- Use of funds
- Proceeds fund the registration-enabling DOMMINO-1 and DOMMINO-2 trials of inobrodib in multiple myeloma.
- Checked
- Announced by the company
- Sources
- CellCentric raises $220M Series D for inobrodib businesswire.com
CellCentric raises $220M Series D for inobrodib pulse2.com